{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T08:11:49Z","timestamp":1779091909578,"version":"3.51.4"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T00:00:00Z","timestamp":1775260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T00:00:00Z","timestamp":1775260800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,6,5]]},"DOI":"10.1038\/s41416-026-03420-2","type":"journal-article","created":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T10:51:28Z","timestamp":1775299888000},"page":"1671-1682","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Nuclear FGF2, androgen receptor and Wnt pathway activation define a targetable subset of antiprogestin-resistant luminal breast cancer"],"prefix":"10.1038","volume":"134","author":[{"given":"Virginia","family":"Figueroa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcela I.","family":"Coianis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Sahores","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela","family":"Pataccini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9206-2369","authenticated-orcid":false,"given":"Mart\u00edn C.","family":"Abba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0766-3838","authenticated-orcid":false,"given":"Andr\u00e9s","family":"El\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"May","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia I.","family":"Vanzulli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Mart\u00ednez V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Burruchaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florencia","family":"Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9170-3988","authenticated-orcid":false,"given":"Carol A.","family":"Sartorius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Lanari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0392-7552","authenticated-orcid":false,"given":"Caroline A.","family":"Lamb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,4]]},"reference":[{"key":"3420_CR1","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.mce.2015.09.035","volume":"418","author":"R Clarke","year":"2015","unstructured":"Clarke R, Tyson JJ, Dixon JM. Endocrine resistance in breast cancer-An overview and update. Mol Cell Endocrinol. 2015;418:220\u201334.","journal-title":"Mol Cell Endocrinol"},{"key":"3420_CR2","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1159\/000351193","volume":"8","author":"N Harbeck","year":"2013","unstructured":"Harbeck N, Thomssen C, Gnant M. St. Gallen 2013: brief preliminary summary of the consensus discussion. Breast Care. 2013;8:102\u20139.","journal-title":"Breast Care"},{"key":"3420_CR3","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1200\/JCO.2013.54.1870","volume":"32","author":"F Ades","year":"2014","unstructured":"Ades F, Zardavas D, Bozovic-Spasojevic I, Pugliano L, Fumagalli D, de Azambuja E, et al. Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. J Clin Oncol. 2014;32:2794\u2013803.","journal-title":"J Clin Oncol"},{"key":"3420_CR4","doi-asserted-by":"crossref","unstructured":"Kunc M, Popeda M, Biernat W, Senkus E, Lost but not least-Novel insights into progesterone receptor loss in estrogen receptor-positive breast cancer. Cancers. 2021;13.","DOI":"10.3390\/cancers13194755"},{"key":"3420_CR5","doi-asserted-by":"publisher","first-page":"djw317","DOI":"10.1093\/jnci\/djw317","volume":"109","author":"PA Rojas","year":"2017","unstructured":"Rojas PA, May M, Sequeira GR, Elia A, Alvarez M, Martinez P, et al. Progesterone receptor isoform ratio: A breast cancer prognostic and predictive factor for antiprogestin responsiveness. J Natl Cancer Inst. 2017;109:djw317.","journal-title":"J Natl Cancer Inst"},{"key":"3420_CR6","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/nature14583","volume":"523","author":"H Mohammed","year":"2015","unstructured":"Mohammed H, Russell IA, Stark R, Rueda OM, Hickey TE, Tarulli GA, et al. Progesterone receptor modulates ERalpha action in breast cancer. Nature. 2015;523:313\u20137.","journal-title":"Nature"},{"key":"3420_CR7","doi-asserted-by":"publisher","first-page":"T49","DOI":"10.1530\/JME-20-0104","volume":"65","author":"KB Horwitz","year":"2020","unstructured":"Horwitz KB, Sartorius CA. 90 YEARS OF PROGESTERONE: Progesterone and progesterone receptors in breast cancer: past, present, future. J Mol Endocrinol. 2020;65:T49\u201363.","journal-title":"J Mol Endocrinol"},{"key":"3420_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-59458-y","volume":"16","author":"MD Mann","year":"2025","unstructured":"Mann MD, Wang M, Ferreon JC, Tsoi PS, Suess MP, Jain A, et al. Structural proteomics defines a sequential priming mechanism for the progesterone receptor. Nat Commun. 2025;16:4403.","journal-title":"Nat Commun"},{"key":"3420_CR9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1158\/1078-0432.CCR-19-0443","volume":"26","author":"O Lee","year":"2019","unstructured":"Lee O, Sullivan ME, Xu Y, Rodgers C, Muzzio M, Helenowski I, et al. Selective progesterone receptor modulators in early stage breast cancer: a randomized, placebo-controlled Phase II window of opportunity trial using telapristone acetate. Clin Cancer Res. 2019;26:25\u201334.","journal-title":"Clin Cancer Res"},{"key":"3420_CR10","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1038\/s41586-025-09684-7","volume":"648","author":"BM Simoes","year":"2025","unstructured":"Simoes BM, Pedley R, McCloskey CW, Roberts M, Reed AD, Twigger AJ, et al. Anti-progestin therapy targets hallmarks of breast cancer risk. Nature. 2025;648:736\u201345.","journal-title":"Nature"},{"key":"3420_CR11","doi-asserted-by":"publisher","first-page":"2680","DOI":"10.1002\/ijc.29304","volume":"136","author":"V Wargon","year":"2015","unstructured":"Wargon V, Riggio M, Giulianelli S, Sequeira GR, Rojas P, May M, et al. Progestin and antiprogestin responsiveness in breast cancer is driven by the PRA\/PRB ratio via AIB1 or SMRT recruitment to the CCND1 and MYC promoters. Int J Cancer. 2015;136:2680\u201392.","journal-title":"Int J Cancer"},{"key":"3420_CR12","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1158\/1078-0432.CCR-22-2060","volume":"29","author":"A Elia","year":"2023","unstructured":"Elia A, Saldain L, Vanzulli SI, Helguero LA, Lamb CA, Fabris V, et al. Beneficial effects of mifepristone treatment in patients with breast cancer selected by the progesterone receptor isoform ratio: Results from the MIPRA trial. Clin Cancer Res. 2023;29:866\u201377.","journal-title":"Clin Cancer Res"},{"key":"3420_CR13","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s10549-020-05527-3","volume":"180","author":"X Garcia","year":"2020","unstructured":"Garcia X, Elia A, Galizzi L, May M, Spengler E, Martinez Vazquez P, et al. Increased androgen receptor expression in estrogen receptor-positive\/progesterone receptor-negative breast cancer. Breast Cancer Res Treat. 2020;180:257\u201363.","journal-title":"Breast Cancer Res Treat"},{"key":"3420_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/bcr3599","volume":"16","author":"DR Cochrane","year":"2014","unstructured":"Cochrane DR, Bernales S, Jacobsen BM, Cittelly DM, Howe EN, D\u2019Amato NC, et al. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Res. 2014;16:R7.","journal-title":"Breast Cancer Res"},{"key":"3420_CR15","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.3390\/ijms25031817","volume":"25","author":"AH Tien","year":"2024","unstructured":"Tien AH, Sadar MD. Treatments targeting the androgen receptor and its splice variants in breast cancer. Int J Mol Sci. 2024;25:1817.","journal-title":"Int J Mol Sci"},{"key":"3420_CR16","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1158\/0008-5472.CAN-09-3746","volume":"70","author":"N Turner","year":"2010","unstructured":"Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, Lopez-Garcia MA, et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res. 2010;70:2085\u201394.","journal-title":"Cancer Res"},{"key":"3420_CR17","doi-asserted-by":"publisher","first-page":"6443","DOI":"10.1158\/1078-0432.CCR-19-0138","volume":"25","author":"JZ Drago","year":"2019","unstructured":"Drago JZ, Formisano L, Juric D, Niemierko A, Servetto A, Wander SA, et al. FGFR1 amplification mediates endocrine resistance but retains TORC sensitivity in metastatic hormone receptor-positive (HR(+)) breast cancer. Clin Cancer Res. 2019;25:6443\u201351.","journal-title":"Clin Cancer Res"},{"key":"3420_CR18","doi-asserted-by":"publisher","first-page":"16052","DOI":"10.18632\/oncotarget.14109","volume":"8","author":"YK Chae","year":"2017","unstructured":"Chae YK, Ranganath K, Hammerman PS, Vaklavas C, Mohindra N, Kalyan A, et al. Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application. Oncotarget. 2017;8:16052\u201374.","journal-title":"Oncotarget"},{"key":"3420_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1406951","volume":"14","author":"A Marin","year":"2024","unstructured":"Marin A, Morales F, Walbaum B. Fibroblast growth factor receptor signaling in estrogen receptor-positive breast cancer: mechanisms and role in endocrine resistance. Front Oncol. 2024;14:1406951.","journal-title":"Front Oncol"},{"key":"3420_CR20","doi-asserted-by":"publisher","first-page":"4379","DOI":"10.1158\/1078-0432.CCR-20-3905","volume":"27","author":"A Servetto","year":"2021","unstructured":"Servetto A, Kollipara R, Formisano L, Lin CC, Lee KM, Sudhan DR, et al. Nuclear FGFR1 regulates gene transcription and promotes antiestrogen resistance in ER(+) breast cancer. Clin Cancer Res. 2021;27:4379\u201396.","journal-title":"Clin Cancer Res"},{"key":"3420_CR21","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1007\/s12672-018-0339-4","volume":"9","author":"A Sahores","year":"2018","unstructured":"Sahores A, Figueroa V, May M, Liguori M, Rubstein A, Fuentes C, et al. Increased high molecular weight FGF2 in endocrine-resistant breast cancer. Horm Cancer. 2018;9:338\u201348.","journal-title":"Horm Cancer"},{"key":"3420_CR22","unstructured":"Institute of Laboratory Animal Resources CoLSNRC. Guide for the care and use of laboratory animals. Washington, D.C.: National Academy Press; 8th Edition, 2011."},{"key":"3420_CR23","doi-asserted-by":"publisher","first-page":"e64049","DOI":"10.1371\/journal.pone.0064049","volume":"8","author":"A Sahores","year":"2013","unstructured":"Sahores A, Luque GM, Wargon V, May M, Molinolo A, Becu-Villalobos D, et al. Novel, low-cost, highly effective, handmade steroid pellets for experimental studies. PLoS One. 2013;8:e64049.","journal-title":"PLoS One"},{"key":"3420_CR24","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1158\/0008-5472.CAN-10-3074","volume":"71","author":"JP Cerliani","year":"2011","unstructured":"Cerliani JP, Guillardoy T, Giulianelli S, Vaque JP, Gutkind JS, Vanzulli SI, et al. Interaction between FGFR-2, STAT5, and Progesterone Receptors in Breast Cancer. Cancer Res. 2011;71:3720\u201331.","journal-title":"Cancer Res"},{"key":"3420_CR25","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s10549-008-0150-y","volume":"116","author":"V Wargon","year":"2009","unstructured":"Wargon V, Helguero LA, Bolado J, Rojas P, Novaro V, Molinolo A, et al. Reversal of antiprogestin resistance and progesterone receptor isoform ratio in acquired resistant mammary carcinomas. Breast Cancer Res Treat. 2009;116:449\u201360.","journal-title":"Breast Cancer Res Treat"},{"key":"3420_CR26","doi-asserted-by":"publisher","first-page":"27793","DOI":"10.1074\/jbc.M202584200","volume":"277","author":"BM Jacobsen","year":"2002","unstructured":"Jacobsen BM, Richer JK, Schittone SA, Horwitz KB. New human breast cancer cells to study progesterone receptor isoform ratio effects and ligand-independent gene regulation. J Biol Chem. 2002;277:27793\u2013800.","journal-title":"J Biol Chem"},{"key":"3420_CR27","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1167\/iovs.12-9423","volume":"53","author":"M Valtink","year":"2012","unstructured":"Valtink M, Knels L, Stanke N, Engelmann K, Funk RH, Lindemann D. Overexpression of human HMW FGF-2 but not LMW FGF-2 reduces the cytotoxic effect of lentiviral gene transfer in human corneal endothelial cells. Invest Ophthalmol Vis Sci. 2012;53:3207\u201314.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3420_CR28","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1093\/bioinformatics\/btp450","volume":"25","author":"M Morgan","year":"2009","unstructured":"Morgan M, Anders S, Lawrence M, Aboyoun P, Pages H, Gentleman R. ShortRead: a bioconductor package for input, quality assessment and exploration of high-throughput sequence data. Bioinformatics. 2009;25:2607\u20138.","journal-title":"Bioinformatics"},{"key":"3420_CR29","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1093\/nar\/gkt214","volume":"41","author":"Y Liao","year":"2013","unstructured":"Liao Y, Smyth GK, Shi W. The Subread aligner: fast, accurate and scalable read mapping by seed-and-vote. Nucleic Acids Res. 2013;41:e108.","journal-title":"Nucleic Acids Res"},{"key":"3420_CR30","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26:139\u201340.","journal-title":"Bioinformatics"},{"key":"3420_CR31","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.1093\/bioinformatics\/btr490","volume":"27","author":"EA Howe","year":"2011","unstructured":"Howe EA, Sinha R, Schlauch D, Quackenbush J. RNA-Seq analysis in MeV. Bioinformatics. 2011;27:3209\u201310.","journal-title":"Bioinformatics"},{"key":"3420_CR32","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1126\/science.1168175","volume":"324","author":"C Tran","year":"2009","unstructured":"Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009;324:787\u201390.","journal-title":"Science"},{"key":"3420_CR33","doi-asserted-by":"publisher","first-page":"293","DOI":"10.15252\/emmm.201606773","volume":"9","author":"G Picco","year":"2017","unstructured":"Picco G, Petti C, Centonze A, Torchiaro E, Crisafulli G, Novara L, et al. Loss of AXIN1 drives acquired resistance to WNT pathway blockade in colorectal cancer cells carrying RSPO3 fusions. EMBO Mol Med. 2017;9:293\u2013303.","journal-title":"EMBO Mol Med"},{"key":"3420_CR34","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1002\/1878-0261.13507","volume":"17","author":"Y Liu","year":"2023","unstructured":"Liu Y, Lei P, Samuel RZ, Kashyap AM, Groth T, Bshara W, et al. Cadherin-11 increases tumor cell proliferation and metastatic potential via Wnt pathway activation. Mol Oncol. 2023;17:2056\u201373.","journal-title":"Mol Oncol"},{"key":"3420_CR35","doi-asserted-by":"publisher","first-page":"5278","DOI":"10.1158\/0008-5472.CAN-05-4610","volume":"66","author":"CS Schuetz","year":"2006","unstructured":"Schuetz CS, Bonin M, Clare SE, Nieselt K, Sotlar K, Walter M, et al. Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis. Cancer Res. 2006;66:5278\u201386.","journal-title":"Cancer Res"},{"key":"3420_CR36","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.steroids.2016.09.004","volume":"114","author":"CH Diep","year":"2016","unstructured":"Diep CH, Ahrendt H, Lange CA. Progesterone induces progesterone receptor gene (PGR) expression via rapid activation of protein kinase pathways required for cooperative estrogen receptor alpha (ER) and progesterone receptor (PR) genomic action at ER\/PR target genes. Steroids. 2016;114:48\u201358.","journal-title":"Steroids"},{"key":"3420_CR37","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1210\/me.2002-0318","volume":"17","author":"X Cui","year":"2003","unstructured":"Cui X, Zhang P, Deng W, Oesterreich S, Lu Y, Mills GB, et al. Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase\/Akt\/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer. Mol Endocrinol. 2003;17:575\u201388.","journal-title":"Mol Endocrinol"},{"key":"3420_CR38","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqae092","volume":"165","author":"CH Diep","year":"2024","unstructured":"Diep CH, Spartz A, Truong TH, Dwyer AR, El-Ashry D, Lange CA. Progesterone receptor signaling promotes cancer-associated fibroblast-mediated tumorigenicity in ER+ breast cancer. Endocrinology. 2024;165:bqae092.","journal-title":"Endocrinology"},{"key":"3420_CR39","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1158\/1541-7786.MCR-20-0554","volume":"19","author":"JW DiGiacomo","year":"2021","unstructured":"DiGiacomo JW, Godet I, Trautmann-Rodriguez M, Gilkes DM. Extracellular Matrix-Bound FGF2 mediates estrogen receptor signaling and therapeutic response in breast cancer. Mol Cancer Res. 2021;19:136\u201349.","journal-title":"Mol Cancer Res"},{"key":"3420_CR40","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1002\/ijc.32252","volume":"145","author":"S Giulianelli","year":"2019","unstructured":"Giulianelli S, Riggio M, Guillardoy T, Perez Pinero C, Gorostiaga MA, Sequeira G, et al. FGF2 induces breast cancer growth through ligand-independent activation and recruitment of ERalpha and PRBDelta4 isoform to MYC regulatory sequences. Int J Cancer. 2019;145:1874\u201388.","journal-title":"Int J Cancer"},{"key":"3420_CR41","doi-asserted-by":"publisher","first-page":"86011","DOI":"10.18632\/oncotarget.13322","volume":"7","author":"D Piasecka","year":"2016","unstructured":"Piasecka D, Kitowska K, Czaplinska D, Mieczkowski K, Mieszkowska M, Turczyk L, et al. Fibroblast growth factor signalling induces loss of progesterone receptor in breast cancer cells. Oncotarget. 2016;7:86011\u201325.","journal-title":"Oncotarget"},{"key":"3420_CR42","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1002\/1878-0261.13274","volume":"16","author":"K Mieczkowski","year":"2022","unstructured":"Mieczkowski K, Kitowska K, Braun M, Galikowska-Bogut B, Gorska-Arcisz M, Piasecka D, et al. FGF7\/FGFR2-JunB signalling counteracts the effect of progesterone in luminal breast cancer. Mol Oncol. 2022;16:2823\u201342.","journal-title":"Mol Oncol"},{"key":"3420_CR43","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1007\/s11934-008-0048-6","volume":"9","author":"MS Lucia","year":"2008","unstructured":"Lucia MS, Lambert JR. Growth factors in benign prostatic hyperplasia: basic science implications. Curr Urol Rep. 2008;9:272\u20138.","journal-title":"Curr Urol Rep"},{"key":"3420_CR44","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1080\/13880209.2018.1564929","volume":"57","author":"BK Park","year":"2019","unstructured":"Park BK, Kim CW, Kwon JE, Negi M, Koo YT, Lee SH, et al. Effects of Lespedeza Cuneata aqueous extract on testosterone-induced prostatic hyperplasia. Pharm Biol. 2019;57:90\u20138.","journal-title":"Pharm Biol"},{"key":"3420_CR45","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1002\/pros.10164","volume":"53","author":"P Rosini","year":"2002","unstructured":"Rosini P, Bonaccorsi L, Baldi E, Chiasserini C, Forti G, De Chiara G, et al. Androgen receptor expression induces FGF2, FGF-binding protein production, and FGF2 release in prostate carcinoma cells: role of FGF2 in growth, survival, and androgen receptor down-modulation. The Prostate. 2002;53:310\u201321.","journal-title":"The Prostate"},{"key":"3420_CR46","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/1097-0045(20000701)44:2<124::AID-PROS5>3.0.CO;2-S","volume":"44","author":"AE Kassen","year":"2000","unstructured":"Kassen AE, Sensibar JA, Sintich SM, Pruden SJ, Kozlowski JM, Lee C. Autocrine effect of DHT on FGF signaling and cell proliferation in LNCaP cells: role of heparin\/heparan-degrading enzymes. Prostate. 2000;44:124\u201332.","journal-title":"Prostate"},{"key":"3420_CR47","doi-asserted-by":"publisher","first-page":"e0304183","DOI":"10.1371\/journal.pone.0304183","volume":"19","author":"AD Gillen","year":"2024","unstructured":"Gillen AD, Hunter I, Ullner E, McEwan IJ. Mechanistic insights into steroid hormone-mediated regulation of the androgen receptor gene. PloS One. 2024;19:e0304183.","journal-title":"PloS One"},{"key":"3420_CR48","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1158\/0008-5472.CAN-12-1857","volume":"73","author":"R Cuevas","year":"2013","unstructured":"Cuevas R, Korzeniewski N, Tolstov Y, Hohenfellner M, Duensing S. FGF-2 disrupts mitotic stability in prostate cancer through the intracellular trafficking protein CEP57. Cancer Res. 2013;73:1400\u201310.","journal-title":"Cancer Res"},{"key":"3420_CR49","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.3390\/cells12071002","volume":"12","author":"A Ardizzone","year":"2023","unstructured":"Ardizzone A, Bova V, Casili G, Repici A, Lanza M, Giuffrida R, et al. Role of basic fibroblast growth factor in cancer: biological activity, targeted therapies, and prognostic value. Cells. 2023;12:1002.","journal-title":"Cells"},{"key":"3420_CR50","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/bjc.1997.5","volume":"75","author":"C Yiangou","year":"1997","unstructured":"Yiangou C, Gomm JJ, Coope RC, Law M, Luqmani YA, Shousha S, et al. Fibroblast growth factor 2 in breast cancer: occurrence and prognostic significance. Br J Cancer. 1997;75:28\u201333.","journal-title":"Br J Cancer"},{"key":"3420_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1078\/0344-0338-00176","volume":"198","author":"A Faridi","year":"2002","unstructured":"Faridi A, Rudlowski C, Biesterfeld S, Schuh S, Rath W, Schroder W. Long-term follow-up and prognostic significance of angiogenic basic fibroblast growth factor (bFGF) expression in patients with breast cancer. Pathol Res Pract. 2002;198:1\u20135.","journal-title":"Pathol Res Pract"},{"key":"3420_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-015-0590-3","volume":"17","author":"S Li","year":"2015","unstructured":"Li S, Payne S, Wang F, Claus P, Su Z, Groth J, et al. Nuclear basic fibroblast growth factor regulates triple-negative breast cancer chemo-resistance. Breast Cancer Res. 2015;17:91.","journal-title":"Breast Cancer Res"},{"key":"3420_CR53","doi-asserted-by":"publisher","first-page":"6471","DOI":"10.1038\/sj.onc.1205838","volume":"21","author":"I Ader","year":"2002","unstructured":"Ader I, Muller C, Bonnet J, Favre G, Cohen-Jonathan E, Salles B, et al. The radioprotective effect of the 24 kDa FGF-2 isoform in HeLa cells is related to an increased expression and activity of the DNA-dependent protein kinase (DNA-PK) catalytic subunit. Oncogene. 2002;21:6471\u20139.","journal-title":"Oncogene"},{"key":"3420_CR54","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s10549-010-0908-x","volume":"126","author":"V Wargon","year":"2011","unstructured":"Wargon V, Fernandez SV, Goin M, Giulianelli S, Russo J, Lanari C. Hypermethylation of the progesterone receptor A in constitutive antiprogestin-resistant mouse mammary carcinomas. Breast Cancer Res Treat. 2011;126:319\u201332.","journal-title":"Breast Cancer Res Treat"},{"key":"3420_CR55","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1146\/annurev-pharmtox-052220-015912","volume":"62","author":"D Westaby","year":"2022","unstructured":"Westaby D, Fenor de La Maza MLD, Paschalis A, Jimenez-Vacas JM, Welti J, de Bono J, et al. A new old target: Androgen receptor signaling and advanced prostate cancer. Annu Rev Pharmacol Toxicol. 2022;62:131\u201353.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"3420_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.102958","volume":"138","author":"N Sridhar","year":"2025","unstructured":"Sridhar N, Iwase T, Xie X, Lee J, Damodaran S, Ueno NT. Paving the path ForwARd: Advances and challenges in androgen receptor targeting in breast cancer. Cancer Treat Rev. 2025;138:102958.","journal-title":"Cancer Treat Rev"},{"key":"3420_CR57","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/s41591-020-01168-7","volume":"27","author":"TE Hickey","year":"2021","unstructured":"Hickey TE, Selth LA, Chia KM, Laven-Law G, Milioli HH, Roden D, et al. The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer. Nat Med. 2021;27:310\u201320.","journal-title":"Nat Med"},{"key":"3420_CR58","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S1470-2045(24)00004-4","volume":"25","author":"C Palmieri","year":"2024","unstructured":"Palmieri C, Linden H, Birrell SN, Wheelwright S, Lim E, Schwartzberg LS, et al. Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, Phase 2 trial. Lancet Oncol. 2024;25:317\u201325.","journal-title":"Lancet Oncol"},{"key":"3420_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10549-009-0436-8","volume":"121","author":"F De Amicis","year":"2010","unstructured":"De Amicis F, Thirugnansampanthan J, Cui Y, Selever J, Beyer A, Parra I, et al. Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat. 2010;121:1\u201311.","journal-title":"Breast Cancer Res Treat"},{"key":"3420_CR60","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1001\/jamaoncol.2016.4975","volume":"3","author":"M Kono","year":"2017","unstructured":"Kono M, Fujii T, Lim B, Karuturi MS, Tripathy D, Ueno NT. Androgen receptor function and androgen receptor-targeted therapies in breast cancer: A review. Jama Oncol. 2017;3:1266\u201373.","journal-title":"Jama Oncol"},{"key":"3420_CR61","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1158\/1541-7786.MCR-16-0167","volume":"14","author":"NC D\u2019Amato","year":"2016","unstructured":"D\u2019Amato NC, Gordon MA, Babbs B, Spoelstra NS, Carson Butterfield KT, Torkko KC, et al. Cooperative dynamics of AR and ER activity in breast cancer. Mol Cancer Res. 2016;14:1054\u201367.","journal-title":"Mol Cancer Res"},{"key":"3420_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-024-00697-5","volume":"10","author":"AD Elias","year":"2024","unstructured":"Elias AD, Staley AW, Fornier M, Vidal GA, Alami V, Sams S, et al. Clinical and immune responses to neoadjuvant fulvestrant with or without enzalutamide in ER+\/Her2- breast cancer. NPJ breast cancer. 2024;10:88.","journal-title":"NPJ breast cancer"},{"key":"3420_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-023-00544-z","volume":"9","author":"AD Elias","year":"2023","unstructured":"Elias AD, Spoelstra NS, Staley AW, Sams S, Crump LS, Vidal GA, et al. Phase II trial of fulvestrant plus enzalutamide in ER+\/HER2- advanced breast cancer. NPJ Breast Cancer. 2023;9:41.","journal-title":"NPJ Breast Cancer"},{"key":"3420_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-06856-3","volume":"15","author":"D Prieto","year":"2025","unstructured":"Prieto D, Rondon-Lagos M, Cruz-Tapias P, Rincon-Riveros A, Rubiano W, De la Pena J, et al. mRNA ratios of AR to ESR1 and PGR distinguish breast cancer subtypes based on public datasets and experimental models. Sci. Rep. 2025;15:21793.","journal-title":"Sci. Rep."}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03420-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03420-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03420-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T08:03:31Z","timestamp":1779091411000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03420-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,4]]},"references-count":64,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,6,5]]}},"alternative-id":["3420"],"URL":"https:\/\/doi.org\/10.1038\/s41416-026-03420-2","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,4]]},"assertion":[{"value":"3 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The use of patient breast cancer samples and clinical data was approved by the Institutional Ethics Committee, Dr. Enrique T. Segura (#CE08\/2016). Written informed consent was obtained from all patients. The study was performed in accordance with the Declaration of Helsinki. Studies involving animals were approved by the IBYME-IACUC Ethical Committee (Protocols 052\/2017 and 014\/2020) and performed in compliance with the ARRIVE guidelines.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}